Waarom krijgt straks iedereen de ziekte van Parkinson?

Scientific Concepts, Discoveries, and Nature/Health Phenomena

Parkinson’s disease as a growing “pandemic”

• Parkinson’s disease is described as the fastest-growing brain disease worldwide, with increasing incidence and a growing overall burden.

Key symptoms (baseline physiology/clinical picture)

Parkinson’s is characterized by both motor and non-motor features:

• Bradykinesia: slowness of movement
• Resting tremor: trembling while at rest
• Asymmetry: symptoms often begin on one side (the cause is described as not fully understood)
• Swallowing and saliva control problems: including drooling
• Severe difficulty with simple motor tasks (e.g., dressing)
• The “invisible part”: non-motor symptoms including:
  • Cognitive and mood changes
  • Urinary/fecal incontinence
  • Sleep problems
  • Sexual dysfunction
  • Pain

Why incidence is rising (risk factors discussed)

• Senescence (aging)
  • Parkinson’s becomes more common with age, but aging alone doesn’t explain the growth.
• Genetics/heredity
  • About ~8 genes are linked to Parkinson’s.
  • Together, these are estimated to explain roughly ~5% of cases.
• Environmental pollution
  • Presented as a major contributor.
• Pesticides and agricultural chemicals
  • Especially agricultural pesticides used since World War II.
  • An epidemiological claim: maps where surface-water pesticide concentration and Parkinson’s occurrence “fit seamlessly.”
  • Occupational/food-chain links described:
    • Higher risk groups such as farmers and wine growers
    • Possible exposure via food (e.g., wine and dairy)
  • A specific risk claim: lifelong consumption of dairy products may pose risk later.
• Animal evidence (toxic mechanism)
  • In mice, pesticide exposure is described as destroying dopamine-relevant brain regions and producing Parkinson’s-like symptoms.

Dopamine neuron loss and the “substantia nigra”

• Parkinson’s is linked to degeneration in the substantia nigra (“black substance”).
• Dopamine decreases over the lifetime.
• A simplified model is used:
  • Starts at ~100% dopamine-producing cells
  • Reaches a visible-threshold around ~20% remaining, at roughly ~110–120 years
• People who develop Parkinson’s are described as reaching that threshold earlier, implying a faster pathological process.

Prodromal phase (pre-diagnosis period)

• A long period of ~10–20 years is described where people already show brain changes (e.g., reduced dopamine) but are not yet diagnosed.

Protein misfolding and “infectious” spread (prion-like behavior)

• Parkinson’s pathology involves incorrect stacking/misfolding of proteins that clump inside nerve cells and kill neurons.
• Prion-like concept:
  • Misfolded/toxic proteins can spread from one neuron to another, inducing other cells to become sick.
• Alpha-synuclein is identified as the key misfolded protein.
• Comparison is made to prion diseases (e.g., mad cow disease), but Parkinson’s is described as slower—decades rather than 3–4 years.

Gut-to-brain spread hypothesis

• The process is suggested to possibly begin in the intestines.
• Spread toward the brain is proposed via the vagus nerve (nervus vagus), described as a “highway” from intestines to brain.
• Proposed staging within the brain:
  • Early involvement of circuitry related to sleep/dreaming
  • REM sleep behavior disorder:
    • People who “live out dreams” during sleep have an estimated ~60–70% chance of developing Parkinson’s later
  • Then progression occurs “domino-like” toward the substantia nigra, and later spreads to much of the rest of the brain—accounting for late-stage complexity and disability.

---

Treatments and Prevention Strategies

Symptom treatment (manage symptoms while understanding causes)

A “train-track” metaphor is used: treat symptoms while also learning how the disease works.

Medication (dopamine-related therapy)

• Medications are described as helping motor symptoms, including freezing (difficulty initiating steps).
• Limitations noted:
  • Time-limited benefit
  • Wearing-off and “over/undershooting,” which can lead to side effects
• Neuropsychiatric/behavioral side effects described:
  • Impulse/risk behaviors (addiction-like tendencies)
  • Sexual and gambling addictions
  • Shopping addiction (described especially for women)
  • Obsessive/compulsive ritual behaviors
  • A narrative about identity/cognitive change (“who am I?”) attributed to medication effects

Non-pharmacological motor strategies

• Parkinson’s is described as having a “broken start engine” (an impaired “autopilot” movement system connected to basal ganglia/“black substance” function).
• Compensatory movement strategies:
  • People develop personalized workarounds, such as:
    • Crossing legs
    • Using a skating-like walking style
  • These approaches are used to bypass impaired automatic initiation.
• ParkinsonNet (Netherlands healthcare network):
  • Integrates physiotherapists with brain knowledge and therapy “tricks.”

Disease-modifying / causal approaches (domino interruption)

• The concept is to stop the spread of misfolded alpha-synuclein using antibodies.
• Potential outcomes proposed:
  • Delaying progression
  • Possibly stopping progression if highly effective
• Timing is emphasized:
  • The prodromal phase (10–20 years before diagnosis) is described as the best window, when spread could be prevented or postponed.

Public health prevention goal

• Reduce environmental exposure to toxic substances (pollution/pesticides).
• Expand fundamental research focused on slowing, stopping, or preventing Parkinson’s.

---

Researchers / Sources Featured

• James Parkinson
  • Noted for writing about the disease in 1817 in England.
• Michael J. Fox
  • Mentioned as a public figure living with Parkinson’s.